- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02423902
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer
September 30, 2021 updated by: Alaunos Therapeutics
A Single-arm, Open-label Study of Ad-RTS-hIL-12 + Veledimex Following First-, Second-, or Third-Line Standard Treatment in Subjects With Locally Advanced or Metastatic Breast Cancer
This is a single-arm, phase Ib/II study to examine the safety, tolerability and preliminary efficacy of one cycle of Ad-RTS-hIL-12 immunotherapy in women with advanced breast cancer and pre-study SD or PR after completion of a minimum 12 week course of standard first- or second-line chemotherapy.
The patient population will include patients with locally advanced or metastatic breast cancer of all subtypes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Subjects who have PD or a CR after the standard chemotherapy are not eligible for the study.
Following entry into the trial, patients will go on a treatment holiday from chemotherapy and enter an immunotherapy phase of treatment.
Continuation of HER2-targeted antibody therapy is permitted during this immunotherapy phase for women with HER2+ disease.
Scans will be conducted at 6 and 12 weeks after the start of Ad-RTS-hIL-12 immunotherapy to determine tumor response.
Radiographic PD at week 6 must be confirmed at least 4 weeks later, either at week 12 or earlier if clinically necessitated.
Study Type
Interventional
Enrollment (Actual)
9
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female, age ≥ 18 years
- Histologically-confirmed, locally advanced or metastatic adenocarcinoma of the breast
- Achievement of SD or PR after a minimum of 12 weeks of pre-study first- or second-line standard chemotherapy
- Presence of at least 2 measurable lesions
- Standard treatment interrupted, except if anti-HER2 therapy
- All treatment-related or radiation-related toxicities resolved to Grade 1 or lower
- Submission of copies of tumor measurements and scans
- Life expectancy > 12 weeks
- ECOG performance status of 0 to 1
- Adequate bone marrow function
- Adequate liver function
- Adequate renal function
- Female subjects and their male partners must agree must agree to use a highly reliable method of birth control
- Able to swallow oral medication
- Willing to comply with study procedures
Exclusion Criteria:
- Metastatic breast cancer patients currently on hormonal therapy as first- or second-line are not permitted
- Prior radiation therapy encompassing > 25% of bone marrow
- Any congenital or acquired condition leading to compromised ability to generate an immune response
Immunosuppressive therapy
- Use of systemic immunosuppressive drugs
- Requirement for continual immune suppression
- Major surgery within 4 weeks of study treatment
- An active, second potentially life-threatening cancer
Presence of brain or subdural metastases
- Any signs and/or symptoms of brain metastases must be stable for ≥ 4 weeks
- Radiographic stability should be determined by comparing contrast-enhanced CT or MRI scans at screening to scans obtained by the same method at least 4 weeks earlier
Presence or documented history of any of the following autoimmune conditions:
- Inflammatory bowel disease
- Rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, autoimmune vasculitis
- Motor neuropathy considered of autoimmune origin
- Presence of meningeal carcinomatosis
- Use of any medications that induce, inhibit, or are substrates of CYP450 3A4
History or evidence of cardiac disease as indicated by any of the following:
- Congestive heart failure greater than NYHA Class II
- Unstable angina or new-onset angina (begun within the last 3 months), or myocardial infarction within the 6 months prior to enrollment
- Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy
- Congenital long QT syndrome or taking drugs known to prolong the QT interval
- Current use of any drugs with a known risk of causing torsades de pointes
- Evidence or history of thromboembolic, venous, or arterial events within the past 3 months
- Evidence or history of bleeding diathesis or coagulopathy
- International normalized ratio (INR) and activated partial thromboplastin time (aPTT) > 1.5 x ULN, in subject who is not therapeutically anticoagulated.
- History of malabsorption syndrome or other condition that would interfere with enteral absorption
- Presence of active clinically serious infection
- Diagnosis of infection with HIV or chronic infection with hepatitis B or C
- Any other unstable or clinically significant concurrent medical condition
- Pregnant or breast-feeding
- Use of any investigational, non-United States Food and Drug Administration (US FDA) approved drug
- Participation in any other clinical trial
- Presence of any condition which makes the patient unsuitable
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ad-RTS-hIL-12 + Veledimex
Intratumoral injection of Ad-RTS-hIL-12 in combination with veledimex
|
Approximately 1.0x10^12 viral particles (vp) per injection
Other Names:
7 oral doses of veledimex
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite measure of safety and tolerability of Ad-RTS-hIL-12 immunotherapy following a first-or second-line standard treatment in HER2-negative subjects, or together with a first- or second-line anti-HER2 antibody therapy in HER2-positive subjects
Time Frame: 2.5 years
|
Composite measure of safety and tolerability based on lab parameters, vitals, physical examination data and deaths, SAEs, and AEs resulting in patient discontinuation.
Toxicity stopping rules when applicable will be determined based on a clinical assessment made by the SRC.
|
2.5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression rate at 12 weeks after the start of one cycle of Ad-RTS-hIL-12 immunotherapy
Time Frame: 2.5 years
|
2.5 years
|
Overall response rate (ORR), defined as the rate of complete response (CR) plus the rate of partial response (PR) at 12 weeks following the start of Ad-RTS-hIL-12 immunotherapy
Time Frame: 2.5 years
|
2.5 years
|
Disease control rate (DCR), defined as the proportion of subjects who have a complete response (CR), partial response (PR), or stable disease (SD) at 12 weeks following the start of one cycle of Ad-RTS-hIL-12 immunotherapy
Time Frame: 2.5 years
|
2.5 years
|
Number of subjects whose baseline tumor status (stable disease or partial response) improves to partial response or better at 12 weeks following the start of Ad-RTS-hIL-12 immunotherapy
Time Frame: 2.5 years
|
2.5 years
|
Comparison of radiographic tumor responses by irRC with RECIST
Time Frame: 2.5 years
|
2.5 years
|
Impact of treatment on serum immune biomarkers such as cytokines, chemokines, soluble receptors and antibodies to tumor antigens
Time Frame: 2.5 years
|
2.5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Francois Lebel, MD, Alaunos Therapeutics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2015
Primary Completion (Actual)
July 1, 2016
Study Completion (Actual)
July 1, 2016
Study Registration Dates
First Submitted
April 6, 2015
First Submitted That Met QC Criteria
April 21, 2015
First Posted (Estimate)
April 22, 2015
Study Record Updates
Last Update Posted (Actual)
October 8, 2021
Last Update Submitted That Met QC Criteria
September 30, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ATI001-203
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
Clinical Trials on Ad-RTS-hIL-12
-
Alaunos TherapeuticsCompleted
-
Alaunos TherapeuticsCompleted
-
Alaunos TherapeuticsCompletedGlioblastoma Multiforme | Anaplastic OligoastrocytomaUnited States
-
Alaunos TherapeuticsTerminatedDiffuse Intrinsic Pontine Glioma | Pediatric Brain TumorUnited States
-
Alaunos TherapeuticsCompleted
-
Alaunos TherapeuticsCompleted
-
Alaunos TherapeuticsCompletedBreast Cancer Nos Metastatic RecurrentUnited States
-
National Cancer Institute (NCI)Completed
-
Wageningen UniversityCompletedEating BehaviorNetherlands
-
Chase Heaton, MDIncyte Corporation; OncoSec Medical IncorporatedTerminatedRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell CarcinomaUnited States